Coherus BioSciences, Inc. - 8-K Summary
Business Context and Reporting Period
Coherus BioSciences, Inc. (CHRS) filed this Current Report on Form 8-K on May 8, 2024. The filing details the entry into a new senior secured term loan and a revenue participation right agreement, alongside the termination of a prior loan agreement.
Key Financial Metrics and Transactions
- New Term Loan: Entered into a senior secured term loan facility of up to $38.7 million, fully funded on May 8, 2024.
- Loan Terms: Matures May 8, 2029; interest rate is 8.00% per annum plus three-month SOFR; interest-only payments quarterly.
- Revenue Participation Agreement: Received a purchase price of $37.5 million in exchange for a mid-single digit percentage of U.S. net sales of UDENYCA and LOQTORZI.
- Repayment Cap: The revenue obligation terminates once the purchaser receives 2.25 times the purchase price (approx. $84.375 million).
- Prior Debt Repayment: Repaid in full the outstanding principal of $75 million under the Prior Loan Agreement.
- Collateral: The new Term Loan is secured by a lien on substantially all company assets, including intellectual property.
Material Changes Versus Prior Period
The company replaced a $75 million prior debt facility with a new $38.7 million term loan and a $37.5 million revenue-based financing instrument. This restructuring reduced the immediate principal debt load but introduced a contingent future payment obligation tied to product sales. The filing does not provide specific revenue, profit, or cash flow figures for the period, as this is a transactional filing rather than a periodic financial report.
Guidance, Risks, and Contingencies
- Prepayment Penalties: Prepayment of the Term Loan incurs fees of 10% (years 1-2), 5% (years 2-3), and 0% (after year 3).
- Default Interest: An additional 4.00% per annum interest applies during an event of default.
- Covenants: The Loan Agreement includes a financial covenant requiring the maintenance of certain cash and cash equivalent levels.
- Buyout Option: The company may buy out the revenue participation rights by paying the 2.25x multiple of the purchase price.
Investor Verification Checklist
- Verify the exact "mid-single digit percentage" of net sales committed to the revenue purchaser.
- Confirm the specific cash and cash equivalent levels required by the new financial covenant.
- Review the full Loan Agreement and Revenue Purchase and Sale Agreement (to be filed as exhibits to the Q2 2024 10-Q) for detailed covenants and exclusions.
- Assess the impact of the 2.25x revenue cap on future cash flow projections for UDENYCA and LOQTORZI.
- Confirm the total cost of the prior debt exit, including the specific prepayment fee and make-whole amount paid.